NCT00328120View on ClinicalTrials.gov

Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

June 30, 2010

Conditions
Advanced Breast Cancer
Interventions
DRUG

Fulvestrant

500 mg intramuscular injection

Trial Locations (5)

Unknown

Research Site, Chiba

Research Site, Fukuoka

Research Site, Nagoyata

Research Site, Osaka

Research Site, Tokyo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00328120 - Faslodex 500mg Multiple Dose Tolerability Study in BC Patients | Biotech Hunter | Biotech Hunter